Michelle Lock

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Covis Pharma Holdings BV engages in the marketing and distribution of therapeutic solutions for patients with life-threatening conditions and chronic illnesses. It offers its products under the Alvesco, Omnaris, Zetonna, Altoprev, Betapace, Betapace AF, Lanoxin, Sular, Prilosec, Zanaflex, Rilutek, Tizanidine Hydrochloride, Nisoldipine, and Riluzole brands. The company was founded in December 2011 and is headquartered in Zug, Switzerland.